Buy the dips, huge volume, $5 tgt. Even analysts gave $5 n higher targets post financing.
Reason for the delayed reaction to getting to fair value is due to financing overhang. With enough volume, that overhang loses its grip. We will be in $5s near term, but the overhang is having its way in the form of dilution and shorts relying on that dilution. Institutions will keep this stock rallying for next couple days. These results were not priced in, the 2nd trial was a lot harder to show efficacy for. Buy the dips.